{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"13.6","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"To estimate the overall survival of patients with refractory/relapsed myelodysplastic Syndrome (MDS) and chronic myelo-monocytic leukemia (CMML) treated with PF-0444913. Overall survival will be defined as the time period between the date of the first dose of drug until the time of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment to be administered on an outpatient basis. All participants to be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles.","id":"OG000","title":"Experimental: PF-04449913 Treatment"}],"paramType":"MEDIAN","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"Up to 2 years, 4 months","title":"Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}